Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)
May 25, 2021 06:26 AM EDT
Deals
Bioregnum

The $70B ques­tion: What’s Pfiz­er go­ing to do with all that Covid vac­cine cash?

Pfiz­er’s lat­est deal a few days ago to sell Eu­rope 1.8 bil­lion dos­es of BioN­Tech’s mR­NA vac­cine — 900 mil­lion guar­an­teed and 900 mil­lion op­tioned …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Judge halts some NIH cuts af­ter 22 states sue

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times